PRMT1、RAP2B在喉癌组织中的表达及与临床病理特征、预后的相关性

The expression of PRMT1 and RAP2B in laryngeal cancer tissue and their correlation with clinical pathological features and prognosis

摘要:

目的：探讨蛋白质精氨酸甲基转移酶1（PRMT1）、Ras相关蛋白2B（RAP2B）在喉癌组织中的表达及与临床病理特征、预后的相关性。方法：选取本院2018年5月至2021年4月经病理组织活检确诊的喉癌患者160例作为观察对象，收集喉癌组织及相应的癌旁组织（距癌组织>5 mm）。采用免疫组化法检测标本PRMT1和RAP2B表达情况，并分析其与临床病理特征的关系；绘制Kaplan-Meier曲线分析PRMT1和RAP2B表达对喉癌患者预后生存率的影响；Cox回归分析影响喉癌患者死亡的风险因素。结果：喉癌组织PRMT1和RAP2B阳性表达率明显高于癌旁组织（P<0.05），且其表达均与临床分期、淋巴结转移均有关（P<0.05），PRMT1表达与雌激素受体α表达情况也有关（P<0.05）；PRMT1阳性表达患者3年生存率明显低于阴性表达患者（65.22% vs 91.18%，P<0.001），RAP2B阳性表达患者3年生存率明显低于阴性表达患者（62.79% vs 91.89%，P<0.001）；PRMT1和RAP2B阳性表达、TNM分期Ⅲ~Ⅳ期、淋巴结转移是喉癌患者死亡的独立危险因素（P<0.05）。结论：在喉癌患者组织中，PRMT1和RAP2B阳性表达率较高，且二者表达与喉癌患者临床病理特征及预后密切相关。

Abstract:

Objective: To investigate the expression of protein arginine methyltransferase 1 (PRMT1) and Ras-associated protein B2 (RAP2B) in laryngeal cancer tissue and their correlation with clinical pathological features and prognosis. Methods: A total of 160 patients with laryngeal cancer confirmed by pathological tissue biopsy in our hospital from May 2018 to April 2021 were regarded as the observation objects. Laryngeal cancer tissue and corresponding adjacent tissues (>5mm away from the cancer tissue) were collected. Immunohistochemistry was applied to detect the expression of PRMT1 and RAP2B in specimens and their relationship with clinical pathological features was analyzed. Kaplan-Meier curve was plotted to analyze the impacts of PRMT1 and RAP2B expression on the prognosis and survival rate of laryngeal cancer patients. Cox regression was applied to analyze the risk factors affecting mortality in laryngeal cancer patients. Results: The positive expression rates of PRMT1 and RAP2B in laryngeal cancer tissue were greatly higher than those in adjacent tissues (P<0.05), and their expression was related to clinical stage and lymph node metastasis (P<0.05), the expression of PRMT1 was also related to the expression of estrogen receptor alpha (P<0.05). The 3-year survival rate of PRMT1 positive expression patients was greatly lower than that of negative expression patients (65.22% vs 91.18%, P<0.001), and the 3-year survival rate of RAP2B positive expression patients was greatly lower than that of negative expression patients (62.79% vs 91.89%, P<0.001). Positive expression of PRMT1 and RAP2B, TNM staging stages III-IV, and lymph node metastasis were independent risk factors for mortality in laryngeal cancer patients (P<0.05). Conclusion: In the tissues of laryngeal cancer patients, the positive expression rates of PRMT1 and RAP2B are relatively high, and their expression is closely related to the clinical pathological features and prognosis of laryngeal cancer patients.